Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. To date, riluzole is the only disease-modifying drug approved for the treatment of ALS, but this has only a minor impact on the clinical outcome. The clinical development of new drugs for ALS is entirely dependent on the understanding of the aetiology and pathophysiology of the disease, which is still far from being fully elucidated. ALS is a multisystem disorder and can be viewed as the consequence of a complex neurodegenerative process involving neuron-glia interactions. Excitotoxicity, oxidative stress, mitochondrial dysfunction, cytoskeletal defects and apoptosis are all putative mechanisms which seem to operate in ALS and might be amenable of pharmacological intervention. Since the pathogenesis of ALS seems to involve multiple factors, future treatments may target different molecular pathways by a combined multi-drug therapy.
Keywords: als, neuroprotection, clinical trials, excitotoxicity, oxidative stress, apoptosis
Current Neuropharmacology
Title: Possible Neuroprotective Strategies in ALS
Volume: 2 Issue: 3
Author(s): Simone Beretta, Laura Brighina and Carlo Ferrarese
Affiliation:
Keywords: als, neuroprotection, clinical trials, excitotoxicity, oxidative stress, apoptosis
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. To date, riluzole is the only disease-modifying drug approved for the treatment of ALS, but this has only a minor impact on the clinical outcome. The clinical development of new drugs for ALS is entirely dependent on the understanding of the aetiology and pathophysiology of the disease, which is still far from being fully elucidated. ALS is a multisystem disorder and can be viewed as the consequence of a complex neurodegenerative process involving neuron-glia interactions. Excitotoxicity, oxidative stress, mitochondrial dysfunction, cytoskeletal defects and apoptosis are all putative mechanisms which seem to operate in ALS and might be amenable of pharmacological intervention. Since the pathogenesis of ALS seems to involve multiple factors, future treatments may target different molecular pathways by a combined multi-drug therapy.
Export Options
About this article
Cite this article as:
Beretta Simone, Brighina Laura and Ferrarese Carlo, Possible Neuroprotective Strategies in ALS, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359684
DOI https://dx.doi.org/10.2174/1570159043359684 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Intercellular Communications in Cerebral Ischemia
Cerebral ischemia, a condition in which there is inadequate blood supply to the brain, ranks as one of the leading causes of disability and mortality globally. Despite its prevalence and severity, efficacious treatment options for this debilitating disorder remain limited. Recent scientific explorations have delved deeply into the pathological mechanisms ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Application of Nanocomposites and Nanoparticles in Treating
Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Brain Cancer-Activated Microglia: A Potential Role for Sphingolipids
Current Medicinal Chemistry Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS
Current Gene Therapy How to Fluorescently Label the Potassium Channel: A Case in hERG
Current Medicinal Chemistry Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Flavonoids as Promising Therapeutics of the Future: A Hub for Cells Survival or Death
Current Medicinal Chemistry Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design Editorial [Hot topic: Endocannabinoid Receptor System (Guest Editor: Robyn A. Puffenbarger)]
CNS & Neurological Disorders - Drug Targets The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies
Current Molecular Medicine Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation
CNS & Neurological Disorders - Drug Targets EDITORIAL [Hot Topic Recognition of Functional Roles of Free Radicals Guest Editor: István Bokkon]
Current Neuropharmacology